Lebensqualität bei Dialysepatienten unter Anämietherapie

Zusammenfassung

Die Lebensqualität (QoL: „Quality of Life“) von Patienten zu beachten und ihre mögliche Verbesserung anzustreben, gehört zu den zentralen ärztlichen Alltagsaufgaben. Bei Dialysepatienten als chronisch Kranken gilt umso mehr, Einschränkungen der QoL systematisch zu erfassen. Die renale Anämie ist ein relevanter Prädiktor eingeschränkter QoL. Mindestens so alt wie die Zulassung von Erythropoese stimulierenden Agenzien (ESAs) ist die Forschung, wie eine spezifische Therapie der renalen Anämie (gleichzeitig) neben dem Hämoglobinwert und harten klinischen Endpunkten auch Aspekte der QoL verbessern helfen kann. Hierbei spielen Substanzwahl und auch der angestrebte Hämoglobin- bzw. Hämatokritwert eine Rolle. Es versteht sich von selbst, dass bei einem subjektiv beurteilten Therapieziel, die individuellen (und vielleicht auch im Verlauf wechselnden) Wünsche der Patienten in die Therapieplanung einbezogen werden sollten.

Publikationsverlauf

Artikel online veröffentlicht:
21. Mai 2025

• Literatur

• 1 Yapa HE, Purtell L, Chambers S. et al. The Relationship Between Chronic Kidney Disease, Symptoms and Health-Related Quality of Life: A Systematic Review. J Ren Care 2020; 46: 74-84
• 2 Fletcher BR, Damery S, Aiyegbusi OL. et al. Symptom burden and health-related quality of life in chronic kidney disease: A global systematic review and meta-analysis. PLoS Med 2022; 19: e1003954
• 3 Verberne WR, van den Wittenboer ID, Voorend CGN. et al. Health-related quality of life and symptoms of conservative care versus dialysis in patients with end-stage kidney disease: a systematic review. Nephrol Dial Transplant 2021; 36: 1418-1433
• 4 Kidney Disease. Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 2024; 105: S117-S314
• 5 Morton RL, Tong A, Howard K. et al. The views of patients and carers in treatment decision making for chronic kidney disease: systematic review and thematic synthesis of qualitative studies. BMJ 2010; 340: c112
• 6 Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N Engl J Med 1996; 334: 835-840
• 7 Hays RD, Kallich JD, Mapes DL. et al. Development of the kidney disease quality of life (KDQOL) instrument. Qual Life Res 1994; 3: 329-338
• 8 Weisbord SD, Fried LF, Arnold RM. et al. Development of a symptom assessment instrument for chronic hemodialysis patients: the Dialysis Symptom Index. J Pain Symptom Manage 2004; 27: 226-240
• 9 Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-483
• 10 Loosman WL, Hoekstra T, van Dijk S. et al. Short-Form 12 or Short-Form 36 to measure quality-of-life changes in dialysis patients?. Nephrol Dial Transplant 2015; 30: 1170-1176
• 11 Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group . KDIGO 2024 Clinical Practice Guideline for Anemia in Chronic Kidney Disease (CKD). Im Internet: Zugriff am 17. Februar 2025 unter: https://kdigo.org/wp-content/uploads/2024/11/KDIGO-2025-Anemia-in-CKD-Guideline_Public-Review-Draft_Nov42024.pdf
• 12 Khan A, Ghulam Hussain S, Mushtaq S. et al. Prevalence and management of anemia and impact of treatment burden on health-related quality of life in chronic kidney disease and dialysis patients. J Pharm Policy Pract 2024; 17: 2427779
• 13 Phillips T, Harris S, Aiyegbusi OL. et al. Potentially modifiable factors associated with health-related quality of life among people with chronic kidney disease: baseline findings from the National Unified Renal Translational Research Enterprise CKD (NURTuRE-CKD) cohort. Clin Kidney J 2024; 17: sfae010
• 14 Shen Y, Wang J, Yuan J. et al. Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE). Anemia among Chinese patients with chronic kidney disease and its association with quality of life – results from the Chinese cohort study of chronic kidney disease (C-STRIDE). BMC Nephrol 2021; 22: 64
• 15 Van Haalen H, Jackson J, Spinowitz B. et al. Impact of chronic kidney disease and anemia on health-related quality of life and work productivity: analysis of multinational real-world data. BMC Nephrol 2020; 21: 88
• 16 Reilly Associates. WPAI General Information. Stand: 2019 Im Internet: Zugriff am 17. Februar 2025 unter: http://www.reillyassociates.net/WPAI_General.html
• 17 Bhandari S, Parfrey P, White C. et al. Predictors of quality of life in patients within the first year of commencing haemodialysis based on baseline data from the PIVOTAL trial and associations with the study outcomes. J Nephrol 2023; 36: 1651-1662
• 18 Diskin J, Diskin CJ. Mental Effects of Excess Parathyroid Hormone in Hemodialysis Patients: A Possible Role for Parathyroid 2 Hormone Receptor?. Ther Apher Dial 2020; 24: 285-289
• 19 Farag YM, Keithi-Reddy SR, Mittal BV. et al. Anemia, inflammation and health-related quality of life in chronic kidney disease patients. Clin Nephrol 2011; 75: 524-533
• 20 Fraser SDS, Phillips T. Quality of life in people with chronic kidney disease: focusing on modifiable risk factors. Curr Opin Nephrol Hypertens 2024; 33: 573-582
• 21 Akizawa T, Pisoni RL, Akiba T. et al. Japanese haemodialysis anaemia management practices and outcomes (1999–2006): results from the DOPPS. Nephrol Dial Transplant 2008; 23: 3643-3653
• 22 Locatelli F, Del Vecchio L. Quality of life: a crucial aspect for the patients, a neglected goal in the treatment of anemia in patients with CKD. Kidney Int 2023; 103: 1025-1027
• 23 Hull KL, Reast J, Clair C. et al. UK survey of patient and caregiver perspectives on the impact of chronic kidney disease-associated anaemia. BMJ Open 2024; 14: e087802
• 24 Jiang JL, Ren W, Song J. et al. The impact of short daily hemodialysis on anemia and the quality of life in Chinese patients. Braz J Med Biol Res 2013; 46: 629-633
• 25 Shepshelovich D, Rozen-Zvi B, Avni T. et al. A. Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis. Am J Kidney Dis 2016; 68: 677-690
• 26 Freburger JK, Ellis AR, Wang L. et al. Comparative Effectiveness of Iron and Erythropoiesis-Stimulating Agent Dosing on Health-Related Quality of Life in Patients Receiving Hemodialysis. Am J Kidney Dis 2016; 67: 271-282
• 27 Agarwal R, Rizkala AR, Bastani B. et al. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol 2006; 26: 445-454
• 28 Macdougall IC, White C, Anker SD. et al. Intravenous Iron in Patients Undergoing Maintenance Hemodialysis. N Engl J Med 2019; 380: 447-458
• 29 Sackeyfio A, Lopes RD, Kovesdy CP. et al. Comparison of outcomes on hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) in anaemia associated with chronic kidney disease: network meta-analyses in dialysis and non-dialysis dependent populations. Clin Kidney J 2023; 17: sfad298
• 30 Chung EY, Palmer SC, Saglimbene VM. et al. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev 2023; 2: CD010590
• 31 Singh AK, Szczech L, Tang KL. et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098
• 32 Pfeffer MA, Burdmann EA, Chen CY. et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-1032
• 33 Drüeke TB, Locatelli F, Clyne N. et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084
• 34 [Anonym] Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group. BMJ 1990; 300: 573-578
• 35 Beusterien KM, Nissenson AR, Port FK. et al. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol 1996; 7: 763-773
• 36 Foley RN, Parfrey PS, Morgan J. et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000; 58: 1325-1335
• 37 Besarab A, Bolton WK, Browne JK. et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590
• 38 Moreno F, Sanz-Guajardo D, López-Gómez JM. et al. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J Am Soc Nephrol 2000; 11: 335-342
• 39 Spinowitz B, Pecoits-Filho R, Winkelmayer WC. et al. Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review. J Med Econ 2019; 22: 593-604
• 40 Collister D, Komenda P, Hiebert B. et al. The Effect of Erythropoietin-Stimulating Agents on Health-Related Quality of Life in Anemia of Chronic Kidney Disease: A Systematic Review and Meta-analysis. Ann Intern Med 2016; 164: 472-478